OMITTED

What the news leaves out.

← Omitted front page

FDA Warns on Unapproved Use of GLP-1 Drugs

5 sources · updated 2026-09-24
Left 0% Center 100% Right 0%
0 left · 2 center · 0 right

What happened

A study reported by The New York Times found that more than 1 million Americans are taking GLP-1 weight-loss drugs without an apparent medical reason. NewsNation reported the figure as over 1.1 million people using GLP-1 drugs without an FDA-approved indication. Researchers said little is known about the risks of these medications for people who do not have an approved condition such as type 2 diabetes or qualifying obesity. Studies cited by NewsNation found that patients who stop GLP-1 drugs can regain about two-thirds of the weight they lost.
Sourcing check · Partly on the record · 5 articles

1 of 5 articles cite a named source for the story. It started with unnamed sources; a named source appeared 8 hours later.

What these terms mean and how they're counted
On the record · names a source 1 of 5
On the record means the article cites a source by name for the story's main claim: a person, or an institution speaking officially, such as a company statement or a named agency's spokesperson. The opposite is an unnamed source. The count is how many of the counted articles cite at least one such source; the names are everyone named across them, each once however the articles spell it. Here: Chintan Dave
Primary evidence · cites a document or data 1 of 5
Primary evidence means the article cites a record you could check yourself: a court filing or ruling, a dataset or report, a recording or transcript, an official statement or press release, market data. A quote is not a document. The count is how many articles cite one. Here: regulatory filing
Credits another outlet 0 of 5
The article says the story comes from another outlet's reporting (“first reported by Reuters”). Those articles relay the story; they are not independent confirmation. Here: Each article presents its own reporting.
Unnamed sources 1 of 5
The main claim is attributed to people who are not identified: “people familiar with the matter”, “officials said”. The count is how many articles do this.
How it developed
When the first report landed and whether it named anyone; when the first named source and the first document appeared. Here: First report Sep 22, 17:40 UTC by New York Times, with no named source. First named source 8 hours later, from NewsNation. First document the next day, from CBS News (regulatory filing).
Not counted 0
Opinion, analysis and video pieces, and articles too short to assess. Every count above is out of the counted articles. An article republished under a new headline is one article.
This is about who is cited, not whether the story is true. Each source below says what it names. How we count
ONE-SIDED THIS WEEK. Only left-leaning outlets have covered this story in the last two days; Washington Examiner reported it on 2026-09-21.
Omitted — what each side leaves out

Unpacked

Right-leaning readers never see the finding that more than 1 million people are taking weight-loss drugs without a medical reason. Left-leaning coverage reports that study result but not that researchers say little is known about the risks for people who lack an approved medical condition, the detail that turns a usage tally into a safety question. Right-leaning outlets had not covered this as of publication. Left-leaning coverage says the users lack "any apparent medical reason." Other reporting on those users frames the group as taking the drugs without an FDA-approved indication, which is a licensing point rather than evidence of no clinical need. Who among that million received a doctor's off-label prescription, and who started with no medical evaluation at all?
Bottom line

A Times reader learns a study found more than 1 million people on GLP-1 drugs with no medical reason, but not that researchers say the risks for that group are unknown. A reader of right-leaning outlets learns neither.

The receipts — 5 facts one side's coverage lacks
  • A study identified more than 1 million people taking weight-loss drugs without any apparent medical reason. numberin The New York Times · absent from right-leaning coverage
  • Over 1.1 million people are using GLP-1 drugs without an FDA-approved reason. numberin NewsNation · absent from right-leaning coverage
  • Patients who stop taking GLP-1 drugs can regain two-thirds of the weight they lost. numberin NewsNation · absent from right-leaning coverage
  • The FDA warned Empower Pharmacy that it violated federal law by making copies of blockbuster weight-loss drugs. official statementin CBS News · absent from right-leaning coverage
  • Patients claim popular GLP-1 drugs led to permanent vision loss. individual casein NewsNation · absent from right-leaning coverage
The Left View
The New York Times framed a new study as showing many Americans use GLP-1 weight-loss drugs without a medical reason, citing more than 1 million people. NewsNation reported over 1.1 million people using the drugs without an FDA-approved reason and that researchers say little is known about the risks for that group. NewsNation also cited weight-regain after stopping the drugs and patient claims of permanent vision loss, while quoting a Rutgers professor that the overall risk-benefit remains strongly positive. CBS News covered related FDA action against compounding pharmacies making cheaper copies of the drugs.
Our Take (balanced)
The story is substantive: multiple outlets report research identifying more than 1 million people using GLP-1 drugs without an FDA-approved medical reason, and researchers have said risks for that population are poorly understood. What is established is that finding as reported. What remains unspecified in the available coverage is the study’s name, authors, data source, and peer-review status. Patient claims of vision loss are alleged, not proven causation. No right-leaning outlet has reported this. Watch for naming or publication of the underlying study, official comments from the FDA or manufacturers, and follow-up data on off-label use and adverse events.

5 sources

More stories

The week's bottom lines, in your inbox

One email a week: the five stories that mattered and what they actually mean. Free.